The Searle Company Limited has achieved a major milestone by securing regulatory approval from the Drug Regulatory Authority of Pakistan (DRAP) to market its Denosumab biosimilar injections in 60mg and 120mg dosages. This marks a significant expansion in locally available options for treating osteoporosis and providing supportive care in oncology.

Rights secured through licensing agreement

Under a licensing agreement with China’s Mabwell Pharmaceuticals, Searle has gained exclusive rights to market and distribute these biosimilar injections in Pakistan. The 60mg dosage targets osteoporosis management, while the 120mg dose is tailored for oncology patients.

Commercial rollout underway

Searle is now gearing up for a commercial launch of both dosages, reinforcing its strategy to enhance its product portfolio, strengthen earnings quality, and maximize shareholder value.

Impact on healthcare access

The approval of these biosimilar Denosumab injections promises to improve access to critical therapies for bone-related health issues, potentially making treatment more affordable and accessible across hospitals and clinics in Pakistan.